APOLLOMICS INC-27 (APLMW)

0.0159  -0.01 (-41.54%)

News Image
2 days ago - Chartmill

Let's take a look at the stocks that are in motion in today's session.

Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes.

News Image
2 days ago - Chartmill

Let's take a look at the stocks that are in motion in today's session.

Intrigued by the market activity in the middle of the day on Wednesday? Uncover the key winners and losers of today's session in our insightful analysis.

News Image
2 days ago - Chartmill

The market is buzzing with gapping stocks on Wednesday. Let's uncover which stocks are experiencing notable gaps during today's session.

Let's have a look at the gap up and gap down stocks in today's session.

News Image
8 days ago - Apollomics Inc.

Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split

The Company's class A ordinary shares will begin trading on a split-adjusted basis on November 25, 2024

News Image
8 days ago - Apollomics Inc.

Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split

The Company's class A ordinary shares will begin trading on a split-adjusted basis on November 25, 2024...

News Image
2 months ago - Apollomics Inc.

Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024

Vebreltinib is efficacious in both treatment naïve and previously treated patients with NSCLC with METex14 skipping, and regardless of co-occurring MET amplification

News Image
3 months ago - Apollomics Inc.

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

FOSTER CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical...

News Image
4 months ago - Apollomics Inc.

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

Continued clinical progress for the vebreltinib registration-enabling program, including new data in non-CNS MET fusion tumors and non-small cell lung...

News Image
4 months ago - Apollomics Inc.

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial

43% overall response rate: Six confirmed responses (including one complete response in metastatic non-small cell lung cancer and five partial responses) confirmed by RECIST 1.1 out of 14 patients with solid tumors harboring MET gene fusions

News Image
4 months ago - Apollomics Inc.

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial

43% overall response rate: Six confirmed responses (including one complete response in metastatic non-small cell lung cancer and five partial responses)...

News Image
4 months ago - Apollomics Inc.

Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference

FOSTER CITY, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical...

News Image
5 months ago - Apollomics Inc.

Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

FOSTER CITY, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical...

News Image
5 months ago - Apollomics Inc.

Apollomics Announces Updated Strategic Focus and Leadership Team Changes

Focus on vebreltinib study enrollment for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations targets greatest unmet medical need

News Image
5 months ago - Apollomics Inc.

Apollomics Announces Updated Strategic Focus and Leadership Team Changes

Focus on vebreltinib study enrollment for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations targets greatest unmet medical need...

News Image
6 months ago - Apollomics Inc.

Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Data from Phase 2 and 2/3 trials demonstrate continued efficacy and safety of vebreltinib for treating different tumor types carrying MET-driver alterations

News Image
7 months ago - Apollomics Inc.

Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene

Apollomics’ partner in China, Avistone, received approval from National Medical Products Administration of China to expand the use of vebreltinib to the...

News Image
8 months ago - Apollomics Inc.

Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Preclinical studies demonstrate vebreltinib is effective for a variety of tumor types carrying MET-driver alterations, and effective for overcoming MET-amplification dependent resistance to EGFR therapies in EGFR-positive non-small cell lung cancer

News Image
8 months ago - Apollomics Inc.

Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Preclinical studies demonstrate vebreltinib is effective for a variety of tumor types carrying MET-driver alterations, and effective for overcoming...

News Image
8 months ago - Apollomics Inc.

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

Continued clinical and regulatory progress for the vebreltinib (APL-101) registration-enabling programCompleted patient enrollment for the uproleselan...

News Image
9 months ago - Apollomics Inc.

Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer

FOSTER CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company...

News Image
10 months ago - Apollomics Inc.

Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

FOSTER CITY, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company...

News Image
10 months ago - Apollomics Inc.

Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Apollomics has an initial 180-day period through July 15, 2024 to regain compliance with Minimum Bid Price Requirement

News Image
10 months ago - Apollomics Inc.

Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Apollomics has an initial 180-day period through July 15, 2024 to regain compliance with Minimum Bid Price Requirement...

News Image
11 months ago - Apollomics Inc.

Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology Conference

FOSTER CITY, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company...

News Image
a year ago - Apollomics Inc.

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

FOSTER CITY, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical...